Vivek Podder: Endocrine Treatments for Patients Diagnosed with Endometrial Cancer in 2025
Vivek Podder, Research Fellow in Gynecological Oncology at Mount Sinai Medical Center of Florida, shared a post on LinkedIn:
“Excited to begin 2025 with our review article, “State of the Art Endocrine Treatments for Patients Diagnosed with Endometrial Cancer in 2025”, which has been published in Current Opinion in Obstetrics and Gynecology.
Co-authored with the incredible team:
• Fernanda Musa, MD
• Kathleen Moore, MD
• Brian Slomovitz, MD (My supervisor)
This article discuss the rising incidence of endometrial cancer (EC), particularly among younger women, and explores current and emerging endocrine therapies. We highlight advances in:
– Fertility-preserving treatments for early-stage EC
– Promising therapies for advanced/recurrent disease
– Biomarkers and molecular profiling refining patient outcomes
– Next-generation agents like SERDs and proteolysis-targeting chimeras.”
State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025
Authors: Fernanda Musa et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023